Brian Bansidhar, DO
Colon & Rectal Surgery · Erie, PANPI 1992891220
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Bristol Myers Squibb at 48.6% of the total. Reporting peaked in 2022 at $574 and has fallen 52.4% since, to $273 in 2025. That places this record below the midpoint for colon & rectal surgery clinicians in PA, where the typical reported total is $2,089.
Across 152 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1K
- AbbVie$405
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$199
- Takeda Pharmaceuticals U.S.A., Inc.$174
- Medtronic$79
- Boston Scientific$59
- plus $222 from 7 others
What the payments were for
- Food & beverage$2,217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 95 | $1,078 |
| AbbVie(2 entities) | 10 | $405 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $174 |
| Medtronic | 3 | $79 |
| Boston Scientific | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 9 | $56 |
| Pfizer | 3 | $53 |
| Johnson & Johnson | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Solventum Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,217 in reported general payments places this provider in the 50th percentile of 108 colon & rectal surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 12 | $571,817 |
| ZeposiaOzanimod Hydrochloride | 26 | $244,898 |
| Balsalazide Disodium | 438 | $64,799 |
| Mesalamine | 144 | $52,595 |
| Mesalamine ErMesalamine | 98 | $44,723 |
| PentasaMesalamine | 23 | $44,051 |
| ErythromycinErythromycin Base | 91 | $40,625 |
| AprisoMesalamine | 30 | $30,804 |
| VoqueznaVonoprazan Fumarate | 12 | $22,353 |
| LialdaMesalamine | 17 | $18,149 |
| Omeprazole | 688 | $16,003 |
| Sulfasalazine DrSulfasalazine | 70 | $7,993 |
| LinzessLinaclotide | 12 | $6,729 |
| Budesonide DrBudesonide | 33 | $6,643 |
| Pantoprazole Sodium | 128 | $3,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $174 | $571,81712 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCApriso | $199 | $30,80430 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $56 | $22,35312 claims |
| Shire North American Group IncLialda | $21 | $18,14917 claims |
| AbbVieLinzess | $405 | $6,72912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 colon & rectal surgery providers in Pennsylvania.
Other colon & rectal surgery in Erie
- Amit SharmaErie$4K
- Jennifer McQuadeErie$3K
- Bogdan ProtyniakWilkes-Barre$429K
- John MarksWynnewood$155K
- Joshua BleierPhiladelphia$86K
- Richard FortunatoPittsburgh$80K
- Najjia MahmoudPhiladelphia$63K
- James McCormickMonroeville$55K
- Juan PoggioPhiladelphia$49K
- Christopher BuzasDanville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.